Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07363434 · ClinicalTrials.gov registry record
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 335
- Enrollment target
NCT07363434 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 335 participants.
The verdict
NCT07363434 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 335 participants
- Enrollment target
Study Summary
The aim of this study was to assess the effectiveness, safety, and tolerability of ribociclib in Indian women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC). This study used secondary data sources, i.e., paper-based records; electronic medical records (EMRs); and other sources, such as radiology reports, pathology reports, and examination/clinician notes related to aBC, from clinics/hospitals across 18 sites in India. Aggregated data of anonymized patients treated with ribociclib plus endocrine therapy (ET) by the approved indication between June 2018 and December 2021 were collected and analyzed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2022-12-21 |
| Est. Completion | 2024-07-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07363434
The ClinicalTrials.gov registry entry for NCT07363434 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07363434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07363434 about?
NCT07363434 is a clinical study titled "A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib". The aim of this study was to assess the effectiveness, safety, and tolerability of ribociclib in Indian women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC). This study used secondary data sources, i.e., paper-based re...
What is the current status of trial NCT07363434?
This trial is currently completed. The enrollment target is 335 participants. The study started on 2022-12-21. Estimated completion is 2024-07-26.
Who is sponsoring clinical trial NCT07363434?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.